Literature DB >> 2790181

Molecular characterization of human factor XSan Antonio.

S V Reddy1, Z Q Zhou, K J Rao, J P Scott, H Watzke, K A High, P Jagadeeswaran.   

Abstract

Enzymatic amplification technique was used to isolate all eight exons and sequences around the splice junctions, putative promoter, and polyadenylation sites of human factor X DNA from a patient with factor X deficiency. Two genetic changes in factor X have been observed in this patient. The patient is most likely a compound heterozygote since there is only 14% activity associated with factor X. A point mutation that resulted in the substitution of cysteine (TGC) for arginine (CGC) at amino acid 366 was found in exon VIII of one allele of the factor X gene. This mutation, which occurs in the catalytic domain, can affect the formation of a disulfide bridge and thus could result in a reduction in factor X activity. Sequencing all the regions revealed a second mutation: a deletion of one nucleotide (TCCT to TCT) in exon VII that would cause a frame shift at amino acid 272 followed by termination. We have also shown that the point mutation in exon VIII creates an ApaL1 restriction site and destroys the HinP1 site. Enzymatic DNA amplification followed by restriction digestion provides a quick, reliable, and sensitive method for carrier detection and antenatal diagnosis in affected kindreds. This is the first characterization of factor X deficiency at the molecular level. We propose to name this mutation Factor XSan Antonio.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2790181

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment.

Authors:  M Krawczak; D N Cooper
Journal:  Hum Genet       Date:  1991-03       Impact factor: 4.132

2.  Molecular genetic analysis of factor X deficiency: gene deletion and germline mosaicism.

Authors:  K Wieland; D S Millar; C B Grundy; R S Mibashan; V V Kakkar; D N Cooper
Journal:  Hum Genet       Date:  1991-01       Impact factor: 4.132

3.  Factor X M402T: a homozygous missense mutation identified as the cause of cross-reacting material-reduced deficiency.

Authors:  Yushi Chikasawa; Keiko Shinozawa; Kagehiro Amano; Kyoichi Ogata; Takeshi Hagiwara; Takashi Suzuki; Hiroshi Inaba; Katsuyuki Fukutake
Journal:  Int J Hematol       Date:  2014-07-27       Impact factor: 2.490

4.  Factor XSanto Domingo. Evidence that the severe clinical phenotype arises from a mutation blocking secretion.

Authors:  H H Watzke; A Wallmark; N Hamaguchi; P Giardina; D W Stafford; K A High
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

Review 5.  Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics.

Authors:  Rodney M Camire
Journal:  J Thromb Thrombolysis       Date:  2021-04-22       Impact factor: 5.221

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.